AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Relmada Therapeutics (RLMD) Soars 82.54% on Narrowed Q4 Loss
Generated by AI AgentAinvest Movers Radar
Wednesday, Apr 23, 2025 6:24 pm ET1min read
Relmada Therapeutics (RLMD) surged 82.54% in today's trading session, marking its third consecutive day of gains and a cumulative increase of 138.10% over the past three days. The share price reached its highest level since December 2024, with an intraday gain of 84.21%.
Relmada Therapeutics reported a narrowed net loss of $0.62 per share in Q4 2024, compared to $0.84 in Q4 2023. This financial improvement contributed to a 4.03% rise in aftermarket trading, reflecting investor optimism about the company's financial health.
In a Wednesday session, the stock price of
experienced a significant surge of 29.84%, reaching $0.49. This surge indicated positive momentum and investor confidence in the company's prospects. However, the stock later faced a decline during the after-hours session, with an additional 11.61% decrease following an earlier 82.54% drop.Relmada Therapeutics also saw a 33.99% increase in its stock price due to investor focus driven by board shakeups and biotech financings. These developments highlighted the company's strategic moves and financial maneuvers, which attracted investor attention and contributed to the stock's volatility.
Ainvest Movers Radar
Knowing stock market today at a glance
Latest Articles
Two Harbors (TWO) Surges 1.59% to Monthly High Amid Anticipation of $1.3B UWM Acquisition
Dec.19 2025
Trane Technologies Surges 1.46% on Q3 Earnings, Analysts Target $550
Dec.19 2025
Rivian (RIVN) Surges 27.34% on Analyst Upgrades, Q3 Revenue Growth Drives Rebound
Dec.19 2025
Tata Chemicals Share Price Soars 119.32% on Novabay Acquisition Drive
Dec.19 2025
X3 Holdings (XTKG) Rallies 36.76% Intraday, 22.50% in Three Sessions on Technical Rebound and Speculative Buying
Dec.19 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet